Eli Lilly describes retatrutide as an investigational triple-agonist treatment for obesity. In its August 2026 results, the company said its Phase 3 clinical package was complete and planned a US Biologics License Application in the first quarter of 2027.
What is known.
The planned filing is a company timetable, not an FDA submission or approval. The forecast asks only whether Lilly confirms that it has submitted the US weight-management application by 31 March.
Why it is a possibility.
Completed late-stage data and a public filing plan make submission more likely than a drug approval in the same period, supporting the provisional 87% estimate.
Lilly still has to finish the regulatory package, including manufacturing information. A new safety finding or an application-preparation delay could push filing past the deadline.
What could prevent it.
A late safety signal, data package issue, or manufacturing delay could move the submission beyond March.
How it will be assessed.
Resolves YES if Lilly publicly confirms that it submitted a US marketing application to the FDA for retatrutide as a chronic weight-management treatment by 31 March 2027. A trial result, pre-submission meeting, or application in another country does not count.
Sources and primary records
Probabilities are provisional editorial estimates, not guarantees. Sources document the present evidence and resolution rule. Read the full disclaimer.